

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of: T. Shantha Raju Serial No.: 09/183,884 Filed: 30 October 1998 For: METHODS AND COMPOSITIONS COMPRISING GLYCOPROTEIN GLYCOFORMS</p>	<p>Group Art Unit: 1634 Examiner: To Be Assigned</p> <p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p>July 2, 1999 <i>Janet Tse</i> Janet Tse</p>
---	---

RECEIVED
JUL 15 1999
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In accordance with the duty imposed by 37 CFR §1.56 to disclose to the Patent Office information coming to the attention of each individual associated with the filing or prosecution of the subject application which may be material to the patentability of any claim of the application, Applicants direct the Examiner's attention to the information listed on the attached Form 1449 (Modified). A copy of the items on the PTO-1449 (Modified) is supplied herewith.

This Information Disclosure Statement is filed before the mailing date of a first Office action on the merits. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 to cover the cost of this Information Disclosure Statement.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any

patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,
GENENTECH, INC.

Date: 2 July 1999

By: 
Jeffrey S. Kubinec
Reg. No. 36,575

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-8228
Fax: (650) 952-9881

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1097R1

Serial No.

09/183,824

Applicant

Raju

Filing Date


30 Oct 1998

Group

1634

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)



OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|---|---|
| 1 | Dwek et al., "Glycobiology: 'the function of sugar in the IgG molecule'" <u>Journal of Anatomy</u> 187:279-292 (Oct 1995) |
| 2 | Lifely et al., "Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions" <u>Glycobiology</u> 5(8):813-822 (Dec 1995) |
| 3 | Raju et al., "Biological significance and structural features of immunoglobulin glycoforms" <u>ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY</u> (Abstract No. 024) vol. 215 (Apr 29, 1998) |
| 4 | Umana et al., "A mathematical model of N-linked glycoform biosynthesis" <u>Biotechnology and Bioengineering</u> 55(6):890-908 (Sep 20, 1997) |
| 5 | Wright and Morrison, "Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1" <u>Journal of Experimental Medicine</u> 180(3):1087-1096 (Sep 1, 1994) |

DO NOT
consider

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.